TIXiMED

TIXiMED is a pharmaceutical company founded in 2021 by Anath Shalev as a spinoff of her research as head of the UAB Comprehensive Diabetes Center. Michael Goodrich of First Avenue Ventures is co-founder and partner in the start-up, which as offices in the Woodward Building.

The company's first product, the oral therapeutic "TIX100", has shown promise in inhibiting thioredoxin-interacting protein (TXNIP) production, and thereby slowing cell death related to Type I and Type II diabetes as well as to nonalcoholic fatty liver disease (NAFLD) which is often associated with diabetes. TIX100 is expected to begin in-human clinical trials in 2023.

References

• Thrailkill, Laurel (January 24, 2023) "UAB startup aiming to reverse effects of diabetes." Birmingham Business Journal

External links

• TIXiMED website